ATARA BIOTHERAPEUTICS, INC. Proceeds from Sale of Short-term Investments
ATARA BIOTHERAPEUTICS, INC. (ATRA) reported Proceeds from Sale of Short-term Investments of $12.51 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-09.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfShortTermInvestments · last filed 2019-05-09
- ATARA BIOTHERAPEUTICS, INC. proceeds from sale of short-term investments for the quarter ending 2019-03-31 was $12.51M, a 65.14% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. proceeds from sale of short-term investments for the quarter ending 2018-12-31 was $49.77M, a 0.73% increase year-over-year.
- ATARA BIOTHERAPEUTICS, INC. proceeds from sale of short-term investments for the quarter ending 2018-09-30 was -$19.09M, a 393.41% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. proceeds from sale of short-term investments for the quarter ending 2018-06-30 was $43.24M, a 78.26% increase year-over-year.
- ATARA BIOTHERAPEUTICS, INC. proceeds from sale of short-term investments for fiscal 2018 was $109.81M, a 2.03% increase from fiscal 2017.
- ATARA BIOTHERAPEUTICS, INC. proceeds from sale of short-term investments for fiscal 2017 was $107.63M, a 55.64% decline from fiscal 2016.
- ATARA BIOTHERAPEUTICS, INC. proceeds from sale of short-term investments for fiscal 2016 was $242.64M, a 279.01% increase from fiscal 2015.
- ATARA BIOTHERAPEUTICS, INC. proceeds from sale of short-term investments for fiscal 2015 was $64.02M, a 1002.27% increase from fiscal 2014.
| Period end | Proceeds from Sale of Short-term Investments 3 month | Proceeds from Sale of Short-term Investments 6 month | Proceeds from Sale of Short-term Investments 9 month | Proceeds from Sale of Short-term Investments 12 month |
|---|---|---|---|---|
| 2019-03-31 | $12.51M 10-Q · filed 2019-05-09 | $62.28M derived: sum of 2 quarters · filed 2019-05-09 | $43.19M derived: sum of 3 quarters · filed 2019-05-09 | $86.43M derived: sum of 4 quarters · filed 2019-05-09 |
| 2018-12-31 | $49.77M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $30.68M derived: sum of 2 quarters · filed 2019-02-26 | $73.92M derived: sum of 3 quarters · filed 2019-02-26 | $109.81M 10-K · filed 2019-02-26 |
| 2018-09-30 | -$19.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $24.15M derived: sum of 2 quarters · filed 2018-11-06 | $60.04M 10-Q · filed 2018-11-06 | $109.45M derived: sum of 4 quarters · filed 2019-05-09 |
| 2018-06-30 | $43.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | $79.13M 10-Q · filed 2018-08-01 | $128.54M derived: sum of 3 quarters · filed 2019-05-09 | $135.04M derived: sum of 4 quarters · filed 2019-05-09 |
| 2018-03-31 | $35.89M 10-Q · filed 2019-05-09 | $85.30M derived: sum of 2 quarters · filed 2019-05-09 | $91.81M derived: sum of 3 quarters · filed 2019-05-09 | $116.06M derived: sum of 4 quarters · filed 2019-05-09 |
| 2017-12-31 | $49.41M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $55.92M derived: sum of 2 quarters · filed 2019-02-26 | $80.17M derived: sum of 3 quarters · filed 2019-02-26 | $107.63M 10-K · filed 2019-02-26 |
| 2017-09-30 | $6.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $30.76M derived: sum of 2 quarters · filed 2018-11-06 | $58.22M 10-Q · filed 2018-11-06 | $113.35M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-06-30 | $24.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | $51.71M 10-Q · filed 2018-08-01 | $106.85M derived: sum of 3 quarters · filed 2019-02-26 | $199.11M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-03-31 | $27.46M 10-Q · filed 2018-05-08 | $82.59M derived: sum of 2 quarters · filed 2019-02-26 | $174.86M derived: sum of 3 quarters · filed 2019-02-26 | $194.23M derived: sum of 4 quarters · filed 2019-02-26 |
| 2016-12-31 | $55.13M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $147.40M derived: sum of 2 quarters · filed 2019-02-26 | $166.78M derived: sum of 3 quarters · filed 2019-02-26 | $242.64M 10-K · filed 2019-02-26 |
| 2016-09-30 | $92.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $111.64M derived: sum of 2 quarters · filed 2017-11-09 | $187.51M 10-Q · filed 2017-11-09 | $217.18M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-06-30 | $19.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $95.24M 10-Q · filed 2017-08-07 | $124.91M derived: sum of 3 quarters · filed 2018-02-27 | $129.67M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-03-31 | $75.87M 10-Q · filed 2017-05-04 | $105.54M derived: sum of 2 quarters · filed 2018-02-27 | $110.30M derived: sum of 3 quarters · filed 2018-02-27 | |
| 2015-12-31 | $29.67M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $34.43M derived: sum of 2 quarters · filed 2018-02-27 | $64.02M 10-K · filed 2018-02-27 | |
| 2015-09-30 | $4.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $34.35M 10-Q · filed 2016-11-04 | ||
| 2015-06-30 | $29.59M 10-Q · filed 2016-08-08 | |||
| 2014-12-31 | $5.81M 10-K · filed 2017-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |